Scarica l'app Stockscreener
59.43
0.17%
0.10
Dopo l'orario di chiusura:
59.12
-0.31
-0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$59.33
Aprire:
$59.27
Volume 24 ore:
12.03M
Relative Volume:
0.61
Capitalizzazione di mercato:
$264.08B
Reddito:
$46.69B
Utile/perdita netta:
$15.29B
Rapporto P/E:
17.31
EPS:
3.4329
Flusso di cassa netto:
$9.25B
1 W Prestazione:
-4.55%
1M Prestazione:
+16.03%
6M Prestazione:
+18.79%
1 anno Prestazione:
-30.36%
Intervallo 1D:
$58.59
$59.91
Intervallo di 1 settimana:
$58.59
$63.99
Portata 52W:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
59.43 | 263.63B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - The Motley Fool
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
Market Trends: What is the next catalyst for ISPCRate Cut & Weekly Setup with ROI Potential - baoquankhu1.vn
Stock Report: Is Novo Nordisk A s b Shares Adrhedged in a consolidation phaseJuly 2025 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" - Finviz
Novo Nordisk ADR: Weight?loss Champion Faces High?Altitude Turbulence - AD HOC NEWS
Novo Nordisk Deepens Cell Therapy Push In Canada As Shares Screen Cheap - Sahm
Key facts: Novo Nordisk stock rises 9.12%; expands diabetes partnership; launches Ozempic ad campaign - TradingView
Is Oral Wegovy a Game Changer for Novo Nordisk? - Finviz
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability - Chartmill
Shorts Report: Can Novo Nordisk A s b Shares Adrhedged be the next market leader - baoquankhu1.vn
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - Finviz
Novo Nordisk (NVO) is "in a Battle," Says Jim Cramer - Finviz
Europe’s ADR Index Was Flat, But Single Stocks Were Not - Finimize
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Finviz
Looking At Novo Nordisk's Recent Unusual Options Activity - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock continue upward trendWeekly Loss Report & Daily Risk Controlled Trade Plans - Улправда
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill - TechStock²
Novo Nordisk A/S (B Shares) ADRhedged (BATS:NVOH) Trading 0.4% Higher – What’s Next? - Defense World
CICC Initiates Coverage on Novo Nordisk with Outperform Rating and $73.50 Price Target for U.S. ADRBN - marketscreener.com
European ADRs Rose In US Trading As Chip And Pharma Led - Finimize
Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spending2026 world cup usa national team semifinals star players high defensive line winner prediction tactical review - Улправда
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost - Sahm
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 - Finviz
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill - Finviz
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.78%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):